Literature DB >> 18428079

Outcomes in major depressive disorder: the evolving concept of remission and its implications for treatment.

Hans-Jürgen Möller1.   

Abstract

It is increasingly recognised that major depressive disorder can be a chronic condition with many patients experiencing recurrent episodes. Remission from a depressive episode implies the absence or near absence of depressive symptoms. However, for many patients the periods between depressive episodes are not symptom free. Residual symptoms are predictors of relapse or recurrence, and may be associated with residual psychosocial impairment. In clinical studies, remission is commonly defined using a cut-off score on a rating scale for depressive symptoms, such as a score of < or = 7 on the 17-item Hamilton scale. However, there is debate about which scales and cut-offs are optimal and full-length rating scales are not widely used in clinical practice. In spite of such issues, it seems clear that a therapy should aim at the most complete remission possible. Unfortunately, recent studies have highlighted that in clinical practice usually only a low rate of remission is achieved. Although long-term treatment with antidepressants can reduce the risk of relapse or recurrence only a minority of patients in clinical practice achieve this as treatment is often prematurely stopped due to long-term side effects such as sleep disturbance, sexual dysfunctioning and weight gain. Therefore, it represents an unmet need to come up with antidepressant drugs of greater efficacy and improved tolerability as such treatments could lead to more complete remission in more patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18428079     DOI: 10.1080/15622970801981606

Source DB:  PubMed          Journal:  World J Biol Psychiatry        ISSN: 1562-2975            Impact factor:   4.132


  22 in total

1.  [Core symptoms of depression].

Authors: 
Journal:  Nervenarzt       Date:  2009-11       Impact factor: 1.214

2.  Improving quality of depression care using organized systems of care: a review of the literature.

Authors:  Wayne Katon; Christine J Guico-Pabia
Journal:  Prim Care Companion CNS Disord       Date:  2011

3.  Psychiatric diagnoses during institutionalization: an investigation of 1334 psychiatric patients hospitalized in an Italian asylum during the 20th century.

Authors:  Roberto Tatarelli; Gianluca Serafini; Marco Innamorati; David Lester; Paolo Girardi; Maurizio Pompili
Journal:  Wien Klin Wochenschr       Date:  2011-03-07       Impact factor: 1.704

Review 4.  Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data.

Authors:  Chi-Un Pae; Andy Forbes; Ashwin A Patkar
Journal:  CNS Drugs       Date:  2011-02       Impact factor: 5.749

Review 5.  Clinical trial design in non-invasive brain stimulation psychiatric research.

Authors:  André Russowsky Brunoni; Felipe Fregni
Journal:  Int J Methods Psychiatr Res       Date:  2011-06       Impact factor: 4.035

6.  Olanzapine and fluoxetine combination therapy for treatment-resistant depression: review of efficacy, safety, and study design issues.

Authors:  William V Bobo; Richard C Shelton
Journal:  Neuropsychiatr Dis Treat       Date:  2009-07-02       Impact factor: 2.570

Review 7.  Management of chronic depressive patients with residual symptoms.

Authors:  Changsu Han; Tzung Lieh Yeh; Masaki Kato; Soichiro Sato; Chia-Ming Chang; Chi-Un Pae
Journal:  CNS Drugs       Date:  2013-05       Impact factor: 5.749

8.  Relationship of residual mood and panic-agoraphobic spectrum phenomenology to quality of life and functional impairment in patients with major depression.

Authors:  Antonella Benvenuti; Paola Rucci; Simona Calugi; Giovanni B Cassano; Mario Miniati; Ellen Frank
Journal:  Int Clin Psychopharmacol       Date:  2010-03       Impact factor: 1.659

9.  Weight-gain in psychiatric treatment: risks, implications, and strategies for prevention and management.

Authors:  Amresh Shrivastava; Megan E Johnston
Journal:  Mens Sana Monogr       Date:  2010-01

Review 10.  Agomelatine: efficacy at each phase of antidepressant treatment.

Authors:  Sidney H Kennedy
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.